Jennifer J. Rhodes net worth and biography

Jennifer Rhodes Biography and Net Worth

Ms. Rhodes joined Angion as Senior Vice President, General Counsel in January 2020. She previously served as General Counsel, Chief Business Officer, Chief Compliance Officer and Corporate Secretary of Adamas Pharmaceuticals, Inc. between April 2016 and January 2020. Before Adamas, Ms. Rhodes served as General Counsel and Corporate Secretary for Medivation, Inc., where she also served as Chief Compliance Officer. Prior to Medivation, Ms. Rhodes was an Assistant General Counsel at Pfizer Inc., where she supported the US primary care business and its primary care medicines development group. Before Pfizer, Ms. Rhodes was a Senior Associate in the Regulatory Law and International Trade Practice at Weil, Gotshal & Manges, LLP. She also served as a law clerk for Chief Judge Gregory A. Carman on the United States Court of International Trade. Ms. Rhodes received a JD from Wake Forest University School of Law and a BA in economics from Tulane University.

What is Jennifer J. Rhodes' net worth?: The estimated net worth of Jennifer J. Rhodes is at least $0.00 as of July 14th, 2021. Ms. Rhodes owns 3,258 shares of Angion Biomedica stock worth more than $0 as of April 26th. This net worth approximation does not reflect any other investments that Ms. Rhodes may own. Additionally, Ms. Rhodes receives a salary of $453,040.00 as Insider at Angion Biomedica. Learn More about Jennifer J. Rhodes' net worth.
How old is Jennifer J. Rhodes?: Ms. Rhodes is currently 53 years old. There are 2 older executives and no younger executives at Angion Biomedica. The oldest executive at Angion Biomedica is Mr. Gregory S. Curhan, Chief Financial Officer, who is 61 years old. Learn More on Jennifer J. Rhodes' age.
What is Jennifer J. Rhodes' salary?: As the Insider of Angion Biomedica Corp., Ms. Rhodes earns $453,040.00 per year. The highest earning executive at Angion Biomedica is Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D., Pres, CEO & Chairman, who commands a salary of $619,880.00 per year. Learn More on Jennifer J. Rhodes' salary.
How do I contact Jennifer J. Rhodes?: The corporate mailing address for Ms. Rhodes and other Angion Biomedica executives is 51 Charles Lindbergh Boulevard, Uniondale NY, 11553. Angion Biomedica can also be reached via phone at 415-655-4899 and via email at [email protected]. Learn More on Jennifer J. Rhodes' contact information.
Has Jennifer J. Rhodes been buying or selling shares of Angion Biomedica?: Jennifer J. Rhodes has not been actively trading shares of Angion Biomedica during the last quarter. Most recently, Jennifer J. Rhodes sold 45 shares of the business's stock in a transaction on Tuesday, December 14th. The shares were sold at an average price of $24.20, for a transaction totalling $1,089.00. Learn More on Jennifer J. Rhodes' trading history.
Who are Angion Biomedica's active insiders?: Angion Biomedica's insider roster includes Itzhak Goldberg (Insider), John Neylan (Insider), Jennifer Rhodes (Insider), and Jay Venkatesan (Insider). Learn More on Angion Biomedica's active insiders.

Jennifer J. Rhodes Insider Trading History at Angion Biomedica

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/14/2021	Sell	45	$24.20	$1,089.00
11/15/2021	Sell	43	$44.00	$1,892.00
10/14/2021	Sell	43	$86.50	$3,719.50
7/21/2021	Sell	43	$109.40	$4,704.20	3,699
7/14/2021	Sell	43	$110.10	$4,734.30	3,258
6/14/2021	Sell	42	$132.70	$5,573.40	3,302
4/15/2021	Sell	39	$150.10	$5,853.90	3,388
3/13/2021	Sell	49	$204.50	$10,020.50	3,428
2/13/2021	Sell	45	$195.40	$8,793.00	3,478

Jennifer J. Rhodes Buying and Selling Activity at Angion Biomedica

Angion Biomedica Company Overview

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.

Today's Range

Now: N/A

50 Day Range

MA: $6.48

$1.00

$10.00

2 Week Range

Now: N/A

Volume

224,800 shs

Average Volume

86,718 shs

Market Capitalization

$30.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

These AI trades triggered this morning (545% return)

From Prosper Trading Academy | Ad

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy

Jennifer Rhodes Biography and Net Worth

What is Jennifer J. Rhodes' net worth?

How old is Jennifer J. Rhodes?

What is Jennifer J. Rhodes' salary?

How do I contact Jennifer J. Rhodes?

Has Jennifer J. Rhodes been buying or selling shares of Angion Biomedica?

Who are Angion Biomedica's active insiders?